ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2850 |
|
1673560-66-1 |
PD-1-IN-17 98+% |
C13H22N6O7 | |
CL2832A |
|
2113650-05-6 |
BMS-1166 hydrochloride 98+% |
C36H34Cl2N2O7 | |
CL2832 |
|
1818314-88-3 |
BMS-1166 98+% |
C36H33ClN2O7 | |
CLA1666 |
|
2329669-72-7 |
Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279) 95+% |
— | |
CLA1320 |
|
1036730-42-3 |
Pidilizumab (Anti-PDCD1 / PD-1 / CD279) 95+% |
— | |
CLA1230 |
|
202833-08-7 |
Atorolimumab 95+% |
— | |
CLA1217 |
|
2411580-63-5 |
Peresolimab (Anti-Human PD-1) 95+% |
— | |
CLA1002 |
|
946414-94-4 |
Nivolumab (anti-PD-1) (Synonyms:BMS-936558; ONO-4538; MDX-1106) 95+% |
— | |
CLA1494 |
|
2394841-59-7 |
Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab) 95+% |
— | |
CLA1021 |
|
1380723-44-3 |
Anti-PDL1 (atezolizumab biosimilar) mAb 98+% |
— | |
CLA1001 |
|
1374853-91-4 |
Anti-Human PD-1 Monoclonal Antibody(Pembrolizumab biosimilar) mAb; MK-3475; Lambrolizumab 95+% |
— | |